Last reviewed · How we verify
Daivobet® gel
Daivobet combines calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis.
Daivobet combines calcipotriene (a vitamin D analog) and betamethasone dipropionate (a corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis (topical treatment).
At a glance
| Generic name | Daivobet® gel |
|---|---|
| Also known as | Taclonex® ointment, Calcipotriol, Betamethasone dipropionate |
| Sponsor | LEO Pharma |
| Drug class | Topical combination therapy (vitamin D analog + corticosteroid) |
| Target | Vitamin D receptor (VDR); glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Calcipotriene acts as a vitamin D receptor agonist that regulates keratinocyte proliferation and differentiation, while betamethasone dipropionate is a potent topical corticosteroid that suppresses inflammatory cytokines and immune cell infiltration. Together, they provide synergistic anti-inflammatory and anti-proliferative effects on psoriatic plaques.
Approved indications
- Plaque psoriasis (topical treatment)
Common side effects
- Application site irritation
- Skin atrophy
- Folliculitis
- Hypercalcemia (with extensive use)
Key clinical trials
- Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis (PHASE2)
- Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis (PHASE2)
- A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris (PHASE2)
- Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis (PHASE3)
- An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris (PHASE1)
- A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) (PHASE2)
- Effect of LEO 80185 Gel on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daivobet® gel CI brief — competitive landscape report
- Daivobet® gel updates RSS · CI watch RSS
- LEO Pharma portfolio CI